Drug name(s)
Isatuximab-irfc Sarclisa® Sarclisa Escena™Indications and usage
Isatuximab-irfc (Sarclisa and Sarclisa Escena) is FDA approved
- In combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor.
- In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
- In combination with bortezomib, lenalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)
Side effects needing medical attention
Sarclisa
- In combination with pomalidomide and dexamethasone: The most common adverse reactions are upper respiratory tract infection, infusion-related reactions, pneumonia, and diarrhea. The most common hematology lab abnormalities are decreased hemoglobin, decreased neutrophils, decreased lymphocytes, and decreased platelets.
- In combination with carfilzomib and dexamethasone: The most common adverse reactions are upper respiratory tract infection, infusion-related reactions, fatigue, hypertension, diarrhea, pneumonia, dyspnea, insomnia, bronchitis, cough, and back pain. The most common hematology lab abnormalities are decreased hemoglobin, decreased lymphocytes, and decreased platelets.
- In combination with bortezomib, lenalidomide and dexamethasone: The most common adverse reactions are upper respiratory tract infections, diarrhea, fatigue, peripheral sensory neuropathy, pneumonia, musculoskeletal pain, cataract, constipation, peripheral edema, rash, infusion-related reaction, insomnia, and COVID-19. The most common hematologic lab abnormalities are decreased hemoglobin, decreased leukocytes, decreased lymphocytes, decreased platelets, and decreased neutrophils.
Sarclisa Escena
- In combination with pomalidomide and dexamethasone: The most common adverse reactions are upper respiratory tract infection, fatigue, pneumonia, musculoskeletal pain, and diarrhea.
- In combination with carfilzomib and dexamethasone: The most common adverse reactions are upper respiratory tract infection and musculoskeletal pain.
- In combination with bortezomib, lenalidomide and dexamethasone: The most common adverse reactions are peripheral neuropathy, constipation, diarrhea, fatigue, musculoskeletal pain, upper respiratory tract infections, injection site reaction, insomnia, edema, rash, and erythema.
- The most common hematology lab abnormalities with any of the combination therapies are decreased neutrophils, decreased platelets, decreased hemoglobin, decreased leukocytes, and decreased lymphocytes.